Clinical Trial Update: Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema [NA]

View source ↗

Summary

Clinical trial update on the use of intravitreal tissue plasminogen activator to treat refractory diabetic macular edema. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Tissue Plasminogen Activator (Alteplase) (Alteplase)

Snippet

Sponsor: Mashhad University of Medical Sciences | Conditions: Diabetic Macular Edema | NA | Status: TERMINATED